High titer recombinant influenza viruses with enhanced replication in MDCK or vero cells or eggs
US10172934B2 · kind B2 · utility
19Cited by
62References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 11, 2017 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | May 11, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16134
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, that confer enhanced growth in cells in culture, such as MDCK cells, or in eggs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.